Literature DB >> 27820120

Successful Treatment of a Complex Vascular Malformation With Sirolimus and Surgical Resection.

Dov C Goldenberg1, Marcelo Carvas, Denise Adams, Marcelo Giannotti, Rolf Gemperli.   

Abstract

Management of complex vascular malformation represents a challenge as it may include a wide variety of options such as embolization, laser therapy, sclerotherapy, and surgical resection but may lead to significant morbidity and is associated with high recurrence rates. In extreme and/or recurrent cases, successful use of sirolimus has been described. We report a case of large unresectable complex venous malformation treated with oral sirolimus for 24 months. Therapy was well tolerated. Patient had substantial improvement in symptoms and shrinkage of the lesion. The Medical Therapy made excision of the malformation possible and patient had a successful surgical procedure. This report provides further evidence that sirolimus should be considered as part of the armamentarium in the management of these rare conditions.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27820120     DOI: 10.1097/MPH.0000000000000702

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  The use of rapamycin to treat vascular tumours and malformations: A single-centre experience.

Authors:  Soumitra Tole; Michelle Fantauzzi; Diana Cottingham; Joao G Amaral; Philip R John; Irene Lara-Corrales; Elena Pope; Manuel D Carcao
Journal:  Paediatr Child Health       Date:  2019-08-20       Impact factor: 2.253

2.  Therapeutic evaluation of sclerotherapy for limb venous malformations: A case series.

Authors:  Tenghui Zhan; Fanggang Cai; Pingfan Guo; Yujie Lian; Hui Zhuang; Jinchi Zhang; Hongyu Chen; Cheng Chen; Yichen Lin
Journal:  Phlebology       Date:  2020-05-29       Impact factor: 1.740

3.  Efficacy and safety of sirolimus in the treatment of vascular malformations: A protocol for systematic review and meta-analysis.

Authors:  Jianyong Dong; Deting Han; Desheng Wang; Huijun Lu; Xiaoliang Wang
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.